NASDAQ:HARP - Harpoon Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.90
  • Forecasted Upside: 629.36 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$2.18
▲ +0.04 (1.87%)

This chart shows the closing price for HARP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Harpoon Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HARP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HARP

Analyst Price Target is $15.90
▲ +629.36% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Harpoon Therapeutics in the last 3 months. The average price target is $15.90, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 629.36% upside from the last price of $2.18.

This chart shows the closing price for HARP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Harpoon Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2022

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2022Roth CapitalBoost Price Target$14.00 ➝ $18.00High
5/16/2022WedbushBoost Price TargetNeutral ➝ Outperform$5.00 ➝ $7.00High
5/13/2022Piper SandlerLower Price Target$15.00 ➝ $14.00Medium
5/9/2022Cantor FitzgeraldReiterated RatingOverweightMedium
3/23/2022Canaccord Genuity GroupLower Price Target$30.00 ➝ $14.00Low
3/23/2022Canaccord Genuity GroupLower Price TargetBuy$30.00 ➝ $14.00High
3/16/2022CitigroupLower Price TargetBuy$14.00 ➝ $7.00High
3/14/2022Roth CapitalLower Price Target$31.00 ➝ $14.00Low
3/14/2022Robert W. BairdLower Price Target$35.00 ➝ $14.00High
3/14/2022HC WainwrightLower Price TargetBuy$31.00 ➝ $18.00High
3/14/2022Piper SandlerLower Price TargetOverweight$27.00 ➝ $15.00High
3/11/2022SVB LeerinkLower Price Target$19.00 ➝ $13.00High
12/16/2021SVB LeerinkReiterated RatingBuyHigh
11/17/2021CitigroupLower Price TargetBuy$16.00 ➝ $14.00Medium
11/11/2021SVB LeerinkLower Price TargetOutperform$25.00 ➝ $19.00High
10/18/2021Cantor FitzgeraldReiterated RatingOverweightLow
9/27/2021CitigroupUpgradeNeutral ➝ Buy$16.00High
8/15/2021Robert W. BairdReiterated RatingBuy$35.00Medium
8/6/2021Piper SandlerReiterated RatingOverweight$35.00 ➝ $30.00Low
8/6/2021SVB LeerinkLower Price TargetOutperform$29.00 ➝ $25.00High
6/8/2021CitigroupDowngradeBuy ➝ NeutralMedium
6/7/2021HC WainwrightReiterated RatingBuy$31.00High
6/7/2021WedbushDowngradeOutperform ➝ NeutralHigh
5/28/2021Cantor FitzgeraldInitiated CoverageOverweight$40.00Medium
5/10/2021Piper SandlerInitiated CoverageOverweight$35.00Medium
5/9/2021SVB LeerinkReiterated RatingBuy$29.00Medium
3/22/2021Robert W. BairdReiterated RatingBuy$35.00High
3/17/2021SVB LeerinkLower Price TargetOutperform$31.00 ➝ $29.00High
3/11/2021SVB LeerinkLower Price TargetOutperform$31.00 ➝ $29.00Medium
1/4/2021SVB LeerinkBoost Price TargetOutperform$28.00 ➝ $31.00N/A
12/23/2020HC WainwrightReiterated RatingBuy$31.00 ➝ $31.00N/A
8/10/2020CitigroupBoost Price TargetBuy$24.00 ➝ $25.00Medium
8/6/2020WedbushBoost Price TargetOutperform$36.00 ➝ $38.00Low
6/30/2020CitigroupBoost Price TargetBuy$23.00 ➝ $24.00Medium
6/1/2020WedbushBoost Price TargetOutperform$26.00 ➝ $36.00High
6/1/2020HC WainwrightReiterated RatingBuyHigh
5/29/2020Roth CapitalBoost Price TargetBuy$25.00 ➝ $31.00High
5/22/2020Piper SandlerInitiated CoverageOverweight$35.00High
5/14/2020HC WainwrightReiterated RatingBuy$28.00Medium
3/13/2020HC WainwrightReiterated RatingBuy$28.00High
2/27/2020SunTrust BanksInitiated CoverageBuy$31.00High
2/3/2020HC WainwrightInitiated CoverageBuy$28.00High
11/13/2019Roth CapitalInitiated CoverageBuy$25.00 ➝ $25.00High
5/24/2019CitigroupReiterated RatingBuy ➝ Buy$23.00High
4/22/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$25.00High
3/5/2019SVB LeerinkReiterated RatingOutperformHigh
3/5/2019WedbushInitiated CoverageOutperform$23.00High
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2021
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/26/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/26/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2022
  • 5 very positive mentions
  • 7 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
3/26/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/25/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
5/25/2022

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Harpoon Therapeutics logo
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $2.18
Low: $1.97
High: $2.39

50 Day Range

MA: $3.36
Low: $1.78
High: $5.02

52 Week Range

Now: $2.18
Low: $1.73
High: $22.74

Volume

279,277 shs

Average Volume

324,012 shs

Market Capitalization

$72.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54

Frequently Asked Questions

What sell-side analysts currently cover shares of Harpoon Therapeutics?

The following Wall Street sell-side analysts have issued reports on Harpoon Therapeutics in the last year: Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Piper Sandler, Robert W. Baird, Roth Capital, SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for HARP.

What is the current price target for Harpoon Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Harpoon Therapeutics in the last year. Their average twelve-month price target is $15.90, suggesting a possible upside of 629.4%.
View the latest price targets for HARP.

What is the current consensus analyst rating for Harpoon Therapeutics?

Harpoon Therapeutics currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HARP will outperform the market and that investors should add to their positions of Harpoon Therapeutics.
View the latest ratings for HARP.

How do I contact Harpoon Therapeutics' investor relations team?

Harpoon Therapeutics' physical mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 443-7400 and its investor relations email address is [email protected] The official website for Harpoon Therapeutics is www.harpoontx.com. Learn More about contacing Harpoon Therapeutics investor relations.